Evidence Hub

Admissibility of Completely Randomized Trials: A Large-Deviation Approach

Guido Imbens, Chao Qin, Stefan Wager

arXiv, 2025

Abstract

When an experimenter has the option of running an adaptive trial, is it admissible to ignore this option and run a non-adaptive trial instead? We provide a negative answer to this question in the best-arm identification problem, where the experimenter aims to allocate measurement efforts judiciously to confidently deploy the most effective treatment arm. We find that, whenever there are at least three treatment arms, there exist simple adaptive designs that universally and strictly dominate non-adaptive completely randomized trials. This dominance is characterized by a notion called efficiency exponent, which quantifies a design's statistical efficiency when the experimental sample is large. Our analysis focuses on the class of batched arm elimination designs, which progressively eliminate underperforming arms at pre-specified batch intervals. We characterize simple sufficient conditions under which these designs universally and strictly dominate completely randomized trials. These results resolve the second open problem posed in Qin [2022].

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free